Related Experiment Video
Updated: Jun 15, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Perimenstrual eletriptan prevents menstrual migraine: an open-label study.
Dawn A Marcus1, Cheryl D Bernstein, Erin A Sullivan
1Department of Anesthesiology & Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Headache
|March 19, 2010
Summary
Perimenstrual eletriptan effectively reduced menstrual migraine (MM) in women. Over half of patients experienced a significant reduction in headache activity, demonstrating the treatment
Area of Science:
- Neurology
- Pharmacology
Background:
- Menstrual migraine (MM) significantly impacts women's health.
- Effective prophylactic treatments for MM are needed.
Purpose of the Study:
- To evaluate the efficacy of perimenstrual eletriptan for reducing headaches in women with prospectively identified MM.
Main Methods:
- 126 female migraineurs completed 3 months of headache diaries.
- Diagnosis of MM was based on International Classification of Headache Disorders (ICHD-II) criteria.
- Eligible women received perimenstrual eletriptan (20 mg TID) for 6 days per cycle for 3 months.
Main Results:
- 74% of women were diagnosed with ICHD-II MM; 61 completed treatment.
- Overall headache activity decreased by 46%.
- 53% of patients achieved 3 migraine-free menstrual periods during treatment.
Conclusions:
- Perimenstrual eletriptan (20 mg TID) is effective in reducing menstrual migraine.
- A significant reduction in headache activity was observed in over half of the patients treated.
